Matinas BioPharma Holdings, Inc.

US$1.19As of Sun 8 Nov 2026, 12:00 UTC
AMEX:MTNBHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR (49.43%)
Div yield —
ROE (141.23%)
Biotechnology
Beta (5Y) 2.25
PE TTM —
TSR TTM (94.25%)
Mkt cap US$1.166M
ROIC (69.38%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$1.29
8.41%
(61.49%)
Hold 3|12|10|0|7
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.01
0.01
0.01
0.01
16.36%
6.19%
9.70%
10.97%
Revenue$M
0.074
0.075
0.076
0.081
10.90%
7.26%
4.80%
12.77%
Peers (US$1.166M)
Cap (US$)
PE
1.218M
—
1.130M
—
Capital
TTM
5Y
10Y
Leveragex
0.426
(0.303)
(0.215)
EBIT/Intx
1.959
0.231
0.235
Own earn%
43.02
(17.15)
(20.05)
Sh yield%
48.02
27.65
29.58
Owners
Insiders/Inst%
11.72
43.41
Short interest%
5.65
SBC / revenue%
3.76
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
10
Op margin range%
17–24
$1 testx
0.0
Incr. ROIC%
4